Search

Your search keyword '"Inganas, M."' showing total 19 results
Start Over Author "Inganas, M."
19 results on '"Inganas, M."'

2. EARLY PROTOTYPES : A STRATEGY FOR EXPLICATING TACIT KNOWLEDGE IN DESIGN ACTIVITIES

Author

Marxt, Christian, Link, P., Inganas, M., Marxt, Christian, Link, P., and Inganas, M.

Abstract

The globalization of design activities has been an ongoing trend in industry for many years and at the same time sparked several research initiatives. One of the major reasons for globalizing design activities lies in accessing the global knowledge pool. Knowledge exchange within this pool is difficult as a large part is only available in implicit form und hence not easily accessible. This paper identifies some of the barriers in explicating knowledge, describes a framework and shows a strategy to overcome these barriers for successful sharing of knowledge and hence development of products or services in global design networks., QC 20110307

Published
2008

3. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer

Author

Berns, P.M.J.J. (Els), Cornelisse, C.J. (Cees), Foekens, J.A. (John), Vossen, R.H.A.M. (Rolf), Look, M.P. (Maxime), Klijn, J.G.M. (Jan), Devilee, P. (Peter), Henzen-Logmans, S.C. (Sonja), Staveren, I.L. (Iris) van, Bakker, B. (Bert), Putten, W.L.J. (Wim) van, Inganas, M., Portengen, H. (Henk), Meijer van Gelder, M.E. (Marion), Claassen, C.J., Berns, P.M.J.J. (Els), Cornelisse, C.J. (Cees), Foekens, J.A. (John), Vossen, R.H.A.M. (Rolf), Look, M.P. (Maxime), Klijn, J.G.M. (Jan), Devilee, P. (Peter), Henzen-Logmans, S.C. (Sonja), Staveren, I.L. (Iris) van, Bakker, B. (Bert), Putten, W.L.J. (Wim) van, Inganas, M., Portengen, H. (Henk), Meijer van Gelder, M.E. (Marion), and Claassen, C.J.

Abstract

TP53 has been implicated in regulation of the cell cycle, DNA repair, and apoptosis. We studied, in primary breast tumors through direct cDNA sequencing of exons 2-11, whether TP53 gene mutations can predict response in patients with advanced disease to either first-line tamoxifen therapy (202 patients, of whom 55% responded) or up-front (poly)chemotherapy (41 patients, of whom 46% responded). TP53 mutations were detected in 90 of 243 (37%) tumors, and one-fourth of these mutations resulted in a premature termination of the protein. The mutations were observed in 32% (65 of 202) of the primary tumors of tamoxifen-treated patients and in 61% (25 of 41) of the primary tumors of the chemotherapy patients. TP53 mutation was significantly associated with a poor response to tamoxifen [31% versus

Published
2000

10. Response on p53

Author

Sjogren, S, Inganas, M, Holmberg, L, Norberg, T, Nordgren, H, Lindgren, A, Bergh, J, Sjogren, S, Inganas, M, Holmberg, L, Norberg, T, Nordgren, H, Lindgren, A, and Bergh, J

Published
1996

15. Pregnancy-Specific β1Glycoprotein, SP1 in Maternal Serum During Uncomplicated Single Pregnancies

Author

Tamsen, L., Inganas, M., Johansson, S. G. O., Kjessler, B., and von Schoultz, B.

Abstract

Pregnancy-specific β1-glycoprotein (SP1) levels in uncomplicated single pregnancies were measured by radio-immunoassay from the time of ovulation until the 8th week of pregnancy in 129 blood samples from 78 women. SP1 was detectable in all samples examined from 34 days after the last menstrual period (LMP), and thereafter the SP1 level increased rapidly with time and 38 to 40 days after LMP the geometric mean SP1 concentration was 90 μg/l. From pregnancy weeks 8 to 41, SP1 levels were measured by nephelo-metry in 1 255 blood samples from 1 255 women. A 95% reference range was established using logarithmic transformation. There was a steady increase in the SP1 concentration until the last month of pregnancy, in which a tendency to level off was seen, the geometric mean levels ranging from 149 to 170 mg/1. The day-to-day variation was studied during 5 consecutive days in 10 women. No significant variation was found. The diurnal variation was studied in blood samples taken every 4th hour during a 24-hour period form 10 women. A significant decrease was found at midnight and at 4 a.m. The elimination rate of SP1 from serum was studied in 10 women following labor. Elimination was non-linear and the time taken for SP1 to decrease to 50% ranged from 24 to 50 hours.No correlation was found between the concentration of SP1 and parity, maternal age, or the sex of the infant. The SP1 concentration was significantly lower in heavier women (> 70 kg) than in lighter women (≤ 70 kg). In some weeks of late pregnancy the SP1 level showed a correlation to placen-tal weight and birth weight of the infant.

Published
1984
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results